精选性阴茎动脉血管栓塞治疗高流量嗜食症 - 为非放射科医生提供一步一步的概述
John P Bretzman1, Matthew J Ziegelmann2, Chris J Reisenauer1
1Department of Radiology, Mayo Clinic, Rochester, MN, United States.
The journal of sexual medicine
|February 7, 2025
概括
选择性血管栓塞是一种有效的治疗高流量嗜食症,提供高成功率,风险最小. 这种微创手术为那些对保守治疗无反应的患者提供了安全的选择.
科学领域:
- 干预性放射学 干预性放射学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 血管外科 血管外科
背景情况:
- 高流量 priapism 需要有效的管理策略.
- 选择性血管栓塞是一种最少侵入性的治疗选择.
研究的目的:
- 描述在高流量吸血症中血管栓塞的指示和技术.
- 概述患者的选择,准备,技术,结果和潜在的并发症.
主要方法:
- 对选择性血管栓塞治疗高流的文献综述.
- 步骤指南步骤指南程序.
主要成果:
- 穿动脉栓塞是最少的侵入性,低风险和有效的.
- 成功率在70%至87%之间.
- 勃起功能障碍报告在7%-19%;并发症通过选择性栓塞和临时药物减轻.
结论:
- 栓塞是一种安全有效的治疗方法,用于非缺血性,高流量的priapism.
- 推给那些对保守治疗没有反应的患者使用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131


